Merck Sharp and Dohme and Dynavax announce cancer research alliance

Merck Sharp and Dohme has announced a new collaboration with Dynavax Technologies in the promising emerging field of immuno-oncology.

The deal encompasses two clinical trial partnerships to investigate the potential benefits of combining Merck's anti-PD-1 therapy Keytruda and its investigational anti-interleukin-10 immunomodulator MK-1966 with Dynavax's investigational toll-like receptor 9 agonist SD-101.

All three of these compounds are immunotherapies designed to enhance the body's own defences in fighting cancer. This first trial will assess SD-101 plus Keytruda in patients with advanced melanoma, while the second will look at SD-101 plus MK-1966 as a treatment for solid or haematological malignancies.

Both studies are expected to be initiated during the second half of 2015.

Dr Eric Rubin, vice-president and therapeutic area head for oncology early-stage development at Merck Research Laboratories, said: "The collaboration with Dynavax is rooted in Merck's commitment to advancing breakthrough science in the field of immuno-oncology in order to address the complex interplay between the immune system and cancer."

Keytruda was recommended for EU approval as a treatment for advanced melanoma by Europe's Committee for Medicinal Products for Human Use last month.